ANG Lifesciences India (BOM:540694) Research & Development: ₹0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540694 ANG Lifesciences India Ltd BOM:540694
63 GF Score
Price ₹34.01
GF Value ₹30.61
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is ANG Lifesciences India Research & Development?

ANG Lifesciences India BOM:540694 +3.47% 63 Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus rates BOM:540694 with a GF Score™ of 63/100 and a GF Value™ of ₹30.61 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ANG Lifesciences India's Research & Development for the three months ended in Mar. 2026 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

ANG Lifesciences India  (BOM:540694) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ANG Lifesciences India Research & Development Related Terms

ANG Lifesciences India Research & Development Historical Data

* Premium members only.

The historical data trend for ANG Lifesciences India's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANG Lifesciences India Research & Development Chart

ANG Lifesciences India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.50 0.00 0.00 0.00 0.00

ANG Lifesciences India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:540694
63GF Score
ANG Lifesciences India Ltd BOM:540694
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANG Lifesciences India Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
ANG Lifesciences India (BOM:540694) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on ANG Lifesciences India and its competitors.
Is ANG Lifesciences India's Research & Development too high?
ANG Lifesciences India's current Research & Development is ₹0.0 Mil. Overall, ANG Lifesciences India has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's Research & Development compare to ZTS and UTHR?
ANG Lifesciences India's Research & Development of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ANG Lifesciences India and its competitors. ANG Lifesciences India's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹30.61, compared to a current price of ₹34.01 — trading 11.1% above its estimated fair value. The current Research & Development is ₹0.0 Mil. ANG Lifesciences India's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?

Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued. The current stock price of ₹34.01 is trading 11.1% above its estimated GF Value™ of ₹30.61. GuruFocus considers ANG Lifesciences India to be Modestly Overvalued.

Key valuation signals for BOM:540694:

  • Research & Development: ₹0.0 Mil
  • GF Value™: ₹30.61 vs. price of ₹34.01 (11.1% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANG Lifesciences India Business Description

Address Ranjit Avenue, B-Block, Darbara Complex, SCO 113, First Floor, District Shopping Complex, Amritsar, PB, IND, 143001
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
63GF Score

Get the complete analysis for BOM:540694

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹34.01
Price
₹30.61
GF Value